15-20 Minutes 2 years Shelf Life SARS-CoV-2 Antigen Self Test Set Saliva Sample Collector Japan 1

test/box

Description

Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status.

The Rapid Antigen Test Device detects the presence of SARS-CoV-2 viral nucleoprotein antigens in nasal and nasopharyngeal secretions. In just 15 minutes, individuals can determine a positive or negative result. If positive, individuals should adhere to their local public health guidelines and verify results with a PCR test.

Date sheet

Advantages of Antigen Rapid Test

Although the development cycle of antigen detection is relatively long, its
1.Sensitivity and specificity are higher than antibody detection
2.The pathogen can be detected at the initial stage of infection
3.Short TAT and simple operation.
4.No professional technicians and equipment are required, and the test can be completed in 15 min.
5.Home use.
6.Personal test.

Details Images

Jiangsu iiLO Biotechnology Co., Ltd. is located in Xukou Town, Wuzhong District, Suzhou City, Jiangsu Province. Suzhou is 100 kilometers away from Shanghai and 200 kilometers away from Nanjing. It is in the center of the Yangtze River Delta Economic Belt. Our main business covers two major sudivisions: BioScience and BioMedicine, including scientific instruments and life science reagents research, medical equipments and diagnostic reagents. From R&D to production and the marketing promotion of products.
We have maintained good business relationship with more than 100 biotechnology companies and customers both domestic and abroad.Our key domestic account including Nanjing University, Wuhan Institute of Virology CAS, etc. And our answering product --disposable collectors (saliva) have been exported to Hong Kong, Southeast Asia, Australia and North America.